TLP
Tri Locum Partners Portfolio holdings
AUM
$330M
This Quarter Return
+11.82%
1 Year Return
+35.44%
3 Year Return
+388.28%
5 Year Return
–
10 Year Return
–
AUM
$328M
AUM Growth
+$328M
(+45%)
Cap. Flow
+$89.2M
Cap. Flow
% of AUM
27.18%
Top 10 Holdings %
Top 10 Hldgs %
53.81%
Holding
92
New
24
Increased
8
Reduced
15
Closed
42
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$35.7M |
| 2 |
Abbott
ABT
|
$17.7M |
| 3 |
Tandem Diabetes Care
TNDM
|
$17M |
| 4 |
CTLT
CATALENT, INC.
CTLT
|
$14.8M |
| 5 |
Illumina
ILMN
|
$14.6M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$12.1M |
| 2 |
West Pharmaceutical
WST
|
$10.5M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$9.55M |
| 4 |
Celldex Therapeutics
CLDX
|
$7.85M |
| 5 |
Stevanato
STVN
|
$7.68M |
Sector Composition
| 1 | Healthcare | 95.57% |
| 2 | Energy | 0.07% |
| 3 | Real Estate | 0.03% |
| 4 | Materials | 0.02% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Regeneron Pharmaceuticals
REGN
$61.5B
| $35.7M | 10.86% |
+43,389
| New | +$35.7M |
|
|
2
West Pharmaceutical
WST
$17.8B
| $23.2M | 7.05% |
66,830
-30,254
| -31% | -$10.5M |
|
|
3
Abbott
ABT
$231B
| $17.7M | 5.39% |
+174,802
| New | +$17.7M |
|
|
4
Tandem Diabetes Care
TNDM
$845M
| $17M | 5.16% |
+417,448
| New | +$17M |
|
5
Eli Lilly
LLY
$657B
| $15.3M | 4.65% |
44,448
-10,021
| -18% | -$3.44M |
|
|
CTLT
6
DELISTED
CATALENT, INC.
CTLT
| $14.8M | 4.51% |
+225,399
| New | +$14.8M |
|
|
7
Illumina
ILMN
$15.8B
| $14.6M | 4.45% |
+62,819
| New | +$14.6M |
|
8
ARK Innovation ETF
ARKK
$7.45B
| $14.1M | 4.3% |
+350,000
| New | +$14.1M |
|
9
Sarepta Therapeutics
SRPT
$1.78B
| $12.3M | 3.73% |
88,961
-30,734
| -26% | -$4.24M |
|
|
AVDL
10
Avadel Pharmaceuticals
AVDL
$1.43B
| $12.2M | 3.7% |
1,327,097
+642,541
| +94% | +$5.89M |
|
11
Merck
MRK
$210B
| $12.2M | 3.7% |
114,242
-12,670
| -10% | -$1.35M |
|
12
Axsome Therapeutics
AXSM
$6.05B
| $9.2M | 2.8% |
149,205
-50,849
| -25% | -$3.14M |
|
13
Thermo Fisher Scientific
TMO
$186B
| $9.16M | 2.79% |
+15,889
| New | +$9.16M |
|
14
Teva Pharmaceuticals
TEVA
$21.1B
| $8.96M | 2.73% |
+1,012,373
| New | +$8.96M |
|
15
Evolent Health
EVH
$1.12B
| $8.7M | 2.65% |
+268,011
| New | +$8.7M |
|
16
Xenon Pharmaceuticals
XENE
$2.98B
| $7.94M | 2.42% |
221,730
+128,366
| +137% | +$4.59M |
|
17
AbbVie
ABBV
$372B
| $7.84M | 2.39% |
+49,213
| New | +$7.84M |
|
18
BioMarin Pharmaceuticals
BMRN
$11.2B
| $7.4M | 2.25% |
76,070
-48,909
| -39% | -$4.76M |
|
|
19
Stevanato
STVN
$6.28B
| $7.19M | 2.19% |
277,467
-296,570
| -52% | -$7.68M |
|
|
RETA
20
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $6.11M | 1.86% |
67,206
-74,260
| -52% | -$6.75M |
|
21
Guardant Health
GH
$8.41B
| $5.98M | 1.82% |
255,011
+124,563
| +95% | +$2.92M |
|
22
Ventyx Biosciences
VTYX
$171M
| $5.12M | 1.56% |
+152,842
| New | +$5.12M |
|
|
23
Apellis Pharmaceuticals
APLS
$3.48B
| $5.08M | 1.55% |
77,048
-144,849
| -65% | -$9.55M |
|
24
uniQure
QURE
$896M
| $4.58M | 1.39% |
+227,273
| New | +$4.58M |
|
25
Inspire Medical Systems
INSP
$2.77B
| $4.1M | 1.25% |
+17,523
| New | +$4.1M |
|